Stable Tetrofosmin Radiopharmaceutical Composition Without Ascorbic Acid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiopharmaceutical compositions of tetrofosmin face challenges with stability, particularly due to the instability of ascorbic acid as a radioprotectant, and require preservatives that complicate storage and handling, while also needing improvements in radiochemical purity and bio-distribution.
Innovation Solution
A stable radiopharmaceutical composition of tetrofosmin is developed without ascorbic acid, using gentisic acid, para-aminobenzoic acid, or maleic acid as radioprotectants, along with stannous chloride as a reductant and transchelators like gluconic acid, to maintain stability and high radiochemical purity, and is produced through a simple and reproducible process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If ascorbic acid is used as a radioprotectant in tetrofosmin composition, then the composition can be stabilized, but the composition becomes unstable when exposed to UV light and has limited shelf-life
Solution Approach 1:
The patent changes the chemical parameter of the radioprotectant from ascorbic acid to alternative compounds such as gentisic acid, para-aminobenzoic acid, or maleic acid. These alternative radioprotectants provide comparable stabilization of the tetrofosmin-technetium complex without the instability issues of ascorbic acid when exposed to UV light, thereby improving shelf-life while maintaining composition stability.
2Stability of the object's composition
If preservatives are added to suppress microorganism growth, then the composition stability is improved, but the device complexity and manufacturing process become more complicated
Solution Approach 1:
The patent extracts and eliminates the need for antimicrobial preservatives by using alternative radioprotectants (gentisic acid, para-aminobenzoic acid, or maleic acid) that provide composition stability without requiring additional preservative agents. This simplifies the formulation by removing the need for multiple additives while maintaining stability.
3Device complexity
If ascorbic acid is used as the sole radioprotectant, then the formulation is simplified, but the radiochemical purity and bio-distribution are compromised
Solution Approach 1:
The patent changes the radioprotectant parameter from ascorbic acid to alternative compounds (gentisic acid, para-aminobenzoic acid, or maleic acid) that maintain formulation simplicity while improving radiochemical purity and bio-distribution characteristics. The alternative radioprotectants provide comparable or superior performance in terms of purity and biodistribution without complicating the formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new composition achieves stability at room temperature for extended periods, maintains high radiochemical purity, and ensures comparable bio-distribution, suitable for diagnostic use with improved manufacturing efficiency.
Implementation Method 1
stannous chloride as a reductant
Implementation Method 2
gentisic acid, para-aminobenzoic acid, or maleic acid as radioprotectants
Implementation Method 3
lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition
Data Source
AI summary
The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.